pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PD-1 · news · pharmadog
← back to PD-1
News · PD-1
63
stories
Aug 7, 26
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
Aug 7, 26
Is the biotech capital of the world moving?
stat
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Jul 30, 26
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
Jul 30, 26
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 28, 26
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
Jul 28, 26
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
Jul 28, 26
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Summit pulls $500M share sale a day after announcing it
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 13, 26
Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies
onclive
May 12, 26
Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
← prev
page 2 of 3
next →
